# Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

> **NCT04069273** · PHASE2 · RECRUITING · sponsor: **Harry H Yoon** · enrollment: 58 (estimated)

## Conditions studied

- Gastric Cancer
- GastroEsophageal Cancer
- Adenocarcinoma

## Interventions

- **DRUG:** Pembrolizumab Monotherapy
- **DRUG:** Ramucirumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04069273
- **Lead sponsor:** Harry H Yoon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-01
- **Primary completion:** 2026-06-11
- **Final completion:** 2026-12-10
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2025-07-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04069273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04069273, "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04069273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*